Source: Drug Discovery and Development

Janssen: Janssen sees Blood Cancer Awareness Month as an opportunity to close the clinical trial diversity gap

September is Blood Cancer Awareness Month. To commemorate the occasion, Janssen (NYSE:JNJ) is working to highlight the importance of cancers such as leukemias, lymphomas and multiple myeloma. Some 1.5 million people in the U.S. are currently living with or in remission from blood cancers, according to the Leukemia & Lymphoma Society. Roughly 35,000 people are diagnosed with...The post Janssen sees Blood Cancer Awareness Month as an opportunity to close the clinical trial diversity gap appeared first on Drug Discovery and Development.

Read full article »
Est. Annual Revenue
$10-50B
Agree?
Est. Employees
10-50K
Agree?
Tom Heyman's photo - CEO of Janssen

CEO

Tom Heyman

CEO Approval Rating

86/100

Read more